WuXi Biologics (Cayman) Inc.

SEHK:2269 Stok Raporu

Piyasa değeri: HK$67.0b

WuXi Biologics (Cayman) Temettü

Temettü kriter kontrolleri 0/6

WuXi Biologics (Cayman) does not have a record of paying a dividend.

Anahtar bilgiler

n/a

Temettü verimi

3.5%

Geri Alım Getirisi

Toplam Hissedar Getirisi3.5%
Gelecekteki Temettü Verimi0%
Temettü Büyümesin/a
Bir sonraki temettü ödeme tarihin/a
Eski temettü tarihin/a
Hisse başına temettün/a
Ödeme oranın/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

After Leaping 29% WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Are Not Flying Under The Radar

Sep 26
After Leaping 29% WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Are Not Flying Under The Radar

WuXi Biologics (Cayman) (HKG:2269) Has A Pretty Healthy Balance Sheet

Sep 12
WuXi Biologics (Cayman) (HKG:2269) Has A Pretty Healthy Balance Sheet

Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Jun 12
Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%

Jun 11
Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%

Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding

Jun 11
Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding

Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly

Apr 15
Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly

Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge

Mar 04
Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge

Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade

Dec 08
Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade

Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

Nov 26
Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

Nov 10
Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?

Sep 26
What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?

These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well

Aug 26
These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well

WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate

Aug 10
WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate

Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?

Jun 19
Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?

Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

May 12
Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

Mar 25
Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?

Mar 13
At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?

Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?

Feb 13
Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?

An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued

Jan 30
An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued

Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?

Dec 09
Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?

Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching

Nov 20
Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching

With EPS Growth And More, WuXi Biologics (Cayman) (HKG:2269) Makes An Interesting Case

Nov 08
With EPS Growth And More, WuXi Biologics (Cayman) (HKG:2269) Makes An Interesting Case

Is WuXi Biologics (Cayman) Inc. (HKG:2269) Trading At A 47% Discount?

Oct 27
Is WuXi Biologics (Cayman) Inc. (HKG:2269) Trading At A 47% Discount?

WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly

Sep 08
WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly

Is Now The Time To Look At Buying WuXi Biologics (Cayman) Inc. (HKG:2269)?

Aug 15
Is Now The Time To Look At Buying WuXi Biologics (Cayman) Inc. (HKG:2269)?

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: Insufficient data to determine if 2269's dividends per share have been stable in the past.

Büyüyen Temettü: Insufficient data to determine if 2269's dividend payments have been increasing.


Piyasaya Karşı Temettü Getirisi

WuXi Biologics (Cayman) Piyasaya Karşı Temettü Getirisi
2269 temettü verimi piyasa ile karşılaştırıldığında nasıldır?
SegmentTemettü Verimi
Şirket (2269)n/a
Pazarın Alt %25'i (HK)3.2%
Pazarın En İyi %25'i (HK)7.9%
Sektör Ortalaması (Life Sciences)1.0%
Analist tahmini (2269) (3 yıla kadar)0%

Önemli Temettü: Unable to evaluate 2269's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Yüksek Temettü: Unable to evaluate 2269's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Insufficient data to calculate 2269's payout ratio to determine if its dividend payments are covered by earnings.


Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as 2269 has not reported any payouts.


Güçlü temettü ödeyen şirketleri keşfedin